Subscribe

Glossary

Prednisone

A steroid that damps inflammation fast. Most of the lifestyle advice in these illnesses exists to offset what this one drug does to you.

Prednisone works, which is why it's still used everywhere. The costs that got measured, though, turn out not to be the ones most people brace themselves for. One of them is your strength rather than your bones.

Quick answerPrednisone is a steroid that damps inflammation fast, and it gets used across all these illnesses. The costs that got measured aren't the ones people expect. One study looked at 198 patients on these drugs, where their steroid dose didn't correlate with their lowest bone score, and being lighter did.
The clearest cost that appeared was about strength rather than bones. One study followed newly diagnosed polymyalgia rheumatica patients, seeing them three months after starting steroids and again 18 months later, and at both visits they scored worse than matched controls on a disability form. At the first visit, 71.2 percent were heading toward frailty against 34.4 percent of controls, which works out at an odds ratio of 4.7. This page gives no doses and no step-down plan, because those belong to whoever prescribes for you, and a dose read off a website is the kind of thing people act on.

What it is and why it's still everywhere

Prednisone is a steroid, and more particularly a made copy of a hormone your adrenal glands produce. It damps inflammation everywhere in the body and it does it fast, which is the reason it stays in use across inflammatory and autoimmune disease whatever else is known about its costs. When something has to be brought under control now, very little else works this quickly.

That mix of real benefit and real cost is what makes this drug hard to write about. A page that only listed the harms would be describing a treatment not worth taking, which isn't the position of anybody who prescribes it. A page that skipped the harms would leave out the reason all the lifestyle advice in these illnesses exists in the first place.

This site holds no source on how the drug works inside a cell, so this page says what it's for rather than how it works. It also gives no dose, no step-down plan, and no expected length of treatment, because those belong to whoever prescribes for you. A figure read off a website is the kind of thing people act on.

What to ask for at the start

Bone protection is the one thing here with a guideline behind it, and the wording is unusually clear. The 2017 American College of Rheumatology guideline covers every adult starting or staying on a long steroid course, at every age. It strongly advises four things: get your calcium and vitamin D right, do weight-bearing and strength-building exercise, stop smoking, and cut back on alcohol. That's one recommendation covering five separate things, all of them outside a prescription.

Two details about it change how you use it. It applies from the day long treatment begins rather than after a problem appears, so ask at the first visit. It also covers all adults on a long steroid course rather than any one illness, so it applies to you whatever you're being treated for.

This page gives no amounts. Our record for that guideline says the full text came back with an error, so the wording got checked against a secondary summary instead and the calcium and vitamin D amounts couldn't be confirmed. Publishing figures this site has not checked would be worse than saying so and pointing the question at your prescriber.

Common misconceptions.

Myth. A low dose means my bones are safe.

Reality. Dose turned out to be a poor guide to it. One study measured 198 patients with these diagnoses, where their steroid dose didn't correlate with their lowest bone score, on either the current dose or the total. Three other things did, which were being lighter, having broken a bone in the spine before, and taking a heartburn drug. Those patients were measured at one moment and most were already on bone protection, so it can't replace a trial, and what it does argue is that you shouldn't read your dose as your risk.

Myth. Steroids make you gain weight, and that's the main problem.

Reality. Weight change is real, and it isn't what the measurements flagged as the bigger issue. In the bone study, being lighter was one of the three things associated with worse bone. In the polymyalgia rheumatica group, two things lasted, and those were disability and heading toward frailty, while body composition changed no differently from the controls over 18 months.

Myth. Once I'm on treatment my function will come back.

Reality. It didn't for everybody in the one study that followed it. Patients scored worse than matched controls on a disability form at three months and again 18 months later, at differences of 0.33 and 0.41. Women slowed down more when walking than female controls, and they were slower getting out of a chair at follow-up. Those last two are subgroup findings, so read them as early hints, and what they argue for is treating your strength as a target of its own.

Myth. A higher steroid dose gets you into remission faster.

Reality. In the one study we hold that tested this, it didn't. In polymyalgia rheumatica, two dose measures failed to predict an early calm spell, where the dose at the first visit came out at a P value of 0.32 and the total steroid taken by three months came out at 0.12. That study looked backward and only watched, so it can't say what dose is right, and what it does argue against is assuming more is better.

Related terms.

References.

  1. Buckley L; Guyatt G; Fink H et al. 2017 American College of Rheumatology Guideline for the Prevention and Treatment of Glucocorticoid‐Induced Osteoporosis. Arthritis & Rheumatology. 2017;69:1521-1537. 10.1002/art.40137GRADE-based clinical practice guideline
  2. Palmowski A; Wiebe E; Muche B et al. Glucocorticoids Are Not Associated with Bone Mineral Density in Patients with Polymyalgia Rheumatica, Giant Cell Arteritis and Other Vasculitides—Cross-Sectional Baseline Analysis of the Prospective Rh-GIOP Cohort. Cells. 2022;11:536. 10.3390/cells11030536Cross-sectional baseline analysis of a prospective cohort
  3. Leung J; De Ross B; Gianoudis J et al. Changes to physical function and body composition during the first 2 years of polymyalgia rheumatica. Rheumatology. 2025;64:5834-5843. 10.1093/rheumatology/keaf375Prospective longitudinal case-control cohort
  4. Hysa E; Balito S; Davoli G et al. Vitamin D Status and Response to Supplementation as Predictive Factors for Early Remission in Polymyalgia Rheumatica: A Retrospective Longitudinal Investigation. Nutrients. 2025;17:2839. 10.3390/nu17172839Retrospective observational case-control study with a longitudinal subgroup

Free download

The First Changes to Make.

The same handout I hand my own patients: the specific food and daily-exposure changes worth making first, no guesswork required.

We'll email you the list and keep your address so we can send you something occasionally. We won't sell it or pass it on, and you can unsubscribe from any email. How we handle it.

No spam · Unsubscribe any time

This page gathers the published research on this subject into one place. The studies behind it were published between 1989 and 2026, and every figure links to the paper it came from. Those studies were peer reviewed. This summary of them was not. Dr. Sarah Luebker is reviewing these pages one at a time and has not reached this one yet, so it carries no medical review date and nothing here is her opinion or her advice to you. Each page gets updated as she reaches it. It is here in the meantime because the science is worth having in one organized place that is easy to find and easy to read. Talk to your own clinician before acting on any of it.